DMKPQ (DMK Pharmaceuticals) Days Sales Outstanding: (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMKPQ DMK Pharmaceuticals Corp DMKPQ
16 GF Score
Price $0.00
View Full Analysis

What is DMK Pharmaceuticals Days Sales Outstanding?

DMK Pharmaceuticals's average Accounts Receivable for the three months ended in Sep. 2023 was $0.00 Mil. DMK Pharmaceuticals's Revenue for the three months ended in Sep. 2023 was $0.01 Mil. Hence, DMK Pharmaceuticals's Days Sales Outstanding for the three months ended in Sep. 2023 was 0.00.

The historical rank and industry rank for DMK Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

DMKPQ's Days Sales Outstanding is not ranked *
in the Drug Manufacturers industry.
Industry Median: 71.98
* Ranked among companies with meaningful Days Sales Outstanding only.

DMK Pharmaceuticals's Days Sales Outstanding declined from Sep. 2022 (79.18) to Sep. 2023 ().

DMK Pharmaceuticals  (OTCPK:DMKPQ) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

DMK Pharmaceuticals Days Sales Outstanding Related Terms

DMK Pharmaceuticals Days Sales Outstanding Historical Data

* Premium members only.

The historical data trend for DMK Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals Days Sales Outstanding Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.02 25.03 139.34 87.40 71.74

DMK Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.18 50.08 66.20 - -

DMKPQ vs CNNC, THCT, VFRM: Days Sales Outstanding Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DMK Pharmaceuticals Days Sales Outstanding vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's Days Sales Outstanding falls into.


DMKPQ
16GF Score
DMK Pharmaceuticals Corp DMKPQ
Days Sales Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DMK Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

DMK Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

Days Sales Outstanding (A: Dec. 2022 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2021 ) + Accounts Receivable (A: Dec. 2022 )) / count ) / Revenue (A: Dec. 2022 )*Days in Period
=( (0.815565 + 1.054058) / 2 ) / 4.756078*365
=0.9348115 / 4.756078*365
=71.74

DMK Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

Days Sales Outstanding (Q: Sep. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2023 ) + Accounts Receivable (A: Sep. 2023 )) / count ) / Revenue (A: Sep. 2023 )*Days in Period
=( (0 + 0) / 1 ) / 0.009062*365 / 4
=0 / 0.009062*365 / 4
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score

Get the complete analysis for DMKPQ

Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price